AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21254911 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 70 mg once weekly
Number of subjects: 135
Study 21254911 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of RLX and ALN
Number of subjects: 135
Study 21254911 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 135
Study 19371824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 6556
Study 19371824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6556
Study 17719326 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy Driver stents (ZES)
Number of subjects: 343
Study 17719326 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 343
Study 15041932 — intervention group
Group type: EXPERIMENTAL
Intervention: ADP 2 microM
Number of subjects: 34
Study 15041932 — intervention group
Group type: EXPERIMENTAL
Intervention: ADP 5 microM
Number of subjects: 34
Study 15041932 — intervention group
Group type: EXPERIMENTAL
Intervention: ADP 10 microM
Number of subjects: 34
Study 10773175 — intervention group
Group type: EXPERIMENTAL
Intervention: Active control groups
Number of subjects: 0
Study 10773175 — intervention group
Group type: COMPARATOR
Intervention: Placebo control groups
Number of subjects: 0
Study 10773175 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved disease taxonomies and severity indices
Number of subjects: 0
Study 9012582 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0
Study 8449578 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mg pivampicillin tablet
Number of subjects: 14
Study 8449578 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mg pivampicillin tablet with food
Number of subjects: 14
Study 8449578 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mg pivampicillin tablet with antacid
Number of subjects: 14
Study 3020162 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) at 10 mg/kg body weight at 8 h intervals for 7 days
Number of subjects: 31
Study 3020162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 31376619 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine in Apidra®
Number of subjects: 0
Study 31376619 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine in Lantus® and Toujeo®
Number of subjects: 0
Study 31376619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31376619 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study 27412502 — intervention group
Group type: EXPERIMENTAL
Intervention: Short message service (SMS) intervention for drug consumption motivation
Number of subjects: 90
Study 27412502 — intervention group
Group type: COMPARATOR
Intervention: Control group with health providers and outreach workers monitoring
Number of subjects: 90
Study 26281910 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' intake of fruit
Number of subjects: 317
Study 26281910 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' intake of vegetables
Number of subjects: 317
Study 26281910 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' intake of sweet snacks
Number of subjects: 317
Study 26281910 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' intake of savoury snacks
Number of subjects: 317
Study 26281910 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' intake of take-away foods
Number of subjects: 317
Study 23691825 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated hearing loss at three levels during Callsign Acquisition Test (CAT) stimuli
Number of subjects: 0
Study 23691825 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent navigation task while performing CAT
Number of subjects: 0
Study 23691825 — intervention group
Group type: COMPARATOR
Intervention: Navigation task with no CAT
Number of subjects: 0
Study 21534749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous low-dose magnesium sulphate (0.75 g/h after a loading dose of 4 g)
Number of subjects: 144
Study 21534749 — intervention group
Group type: COMPARATOR
Intervention: Standard intramuscular regimen (as advocated by Pritchard)
Number of subjects: 144
Study 21534749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous low-dose magnesium sulphate
Number of subjects: 144
Study 21534749 — intervention group
Group type: COMPARATOR
Intervention: Standard intramuscular regimen
Number of subjects: 144
Study 19486260 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-fat dairy supplementation (3.5 servings/day)
Number of subjects: 45
Study 19486260 — intervention group
Group type: COMPARATOR
Intervention: Low-fat dairy supplementation (3.5 servings/day)
Number of subjects: 45
Study 19486260 — intervention group
Group type: COMPARATOR
Intervention: Comparison of whole-fat vs low-fat dairy
Number of subjects: 45
Study 16438759 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (2 g in 100 mL of saline solution)
Number of subjects: 100
Study 16438759 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mL of saline)
Number of subjects: 100
Study 12778857 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-phosphorus diet
Number of subjects: 51
Study 12778857 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate 2.5 g/day
Number of subjects: 51
Study 12778857 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate 5 g/day
Number of subjects: 51
Study 10746617 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg tid)
Number of subjects: 30
Study 10746617 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tid)
Number of subjects: 30
Study 8694170 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed propofol at 37 degrees C
Number of subjects: 101
Study 8694170 — intervention group
Group type: COMPARATOR
Intervention: Room temperature propofol
Number of subjects: 101
Study 1510454 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of rifampin twice daily on study days 6 and 7 (group A)
Number of subjects: 14
Study 1510454 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of rifampin once daily on days 4, 5, 6, and 7 (group B)
Number of subjects: 14
Study 1510454 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 14
Study 1510454 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day regimen (group B)
Number of subjects: 14
Study 6625963 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dialysis
Number of subjects: 7
Study 6625963 — intervention group
Group type: COMPARATOR
Intervention: Inactive dialysis
Number of subjects: 7
Study 6625963 — intervention group
Group type: COMPARATOR
Intervention: Sham dialysis
Number of subjects: 7
Study 6625963 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dialysis and Inactive dialysis
Number of subjects: 7
Study 6625963 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma from patients during dialysis
Number of subjects: 7
Study 31910649 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine CMR
Number of subjects: 500
Study 31910649 — intervention group
Group type: COMPARATOR
Intervention: Selective CMR
Number of subjects: 500
Study 31910649 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific HF causes from imaging
Number of subjects: 500
Study 31910649 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific HF causes from imaging
Number of subjects: 500
Study 31910649 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific HF causes from clinical assessment
Number of subjects: 500
Study 31910649 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific HF causes from clinical assessment
Number of subjects: 500
Study 30554783 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg pegbelfermin once a day
Number of subjects: 75
Study 30554783 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg pegbelfermin once a week
Number of subjects: 75
Study 30554783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 28601693 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse reasoning training (n = 64)
Number of subjects: 187
Study 28601693 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy sensory-based reasoning (n = 65)
Number of subjects: 187
Study 28601693 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 58)
Number of subjects: 187
Study 27592038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical physical therapy for 6 weeks (12 sessions)
Number of subjects: 38
Study 24094133 — intervention group
Group type: EXPERIMENTAL
Intervention: Website trust cue factor
Number of subjects: 0
Study 24094133 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived DTC website trust
Number of subjects: 0
Study 23318238 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-centred eco-bio-social intervention
Number of subjects: 1200
Study 23318238 — intervention group
Group type: COMPARATOR
Intervention: Routine service area (control)
Number of subjects: 1200
Study 20561917 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazobactam/piperacillin (TAZ/PIPC) 5 g intravenously every 12 h
Number of subjects: 100
Study 20561917 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (IPM/CS) 1 g intravenously every 12 h
Number of subjects: 100
Study 17605234 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (RS) 30 g/d for 4 weeks
Number of subjects: 40
Study 17605234 — intervention group
Group type: COMPARATOR
Intervention: Control group (received RS in late 4 weeks)
Number of subjects: 40
Study 15618801 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous double epidural catheter technique with ropivacaine 0.3%
Number of subjects: 30
Study 15618801 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous morphine
Number of subjects: 30
Study 11868800 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg daily for 5 days + 80 mg lovastatin
Number of subjects: 12
Study 11868800 — intervention group
Group type: COMPARATOR
Intervention: 80 mg lovastatin alone
Number of subjects: 12
Study 10594528 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg DDAVP
Number of subjects: 18
Study 10594528 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg DDAVP
Number of subjects: 18
Study 10594528 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg DDAVP
Number of subjects: 18
Study 10594528 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18
Study 7491848 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 49
Study 1639906 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated high-performance liquid chromatographic method for rifampicin analysis
Number of subjects: 0
Study 6093511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 1 g
Number of subjects: 8
Study 6093511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 1 g
Number of subjects: 8
Study 6093511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 0.5 g
Number of subjects: 8
Study 31184022 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (Brudi PLUS) 350 mg, 3 times a day for 90 days
Number of subjects: 109
Study 31184022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 31184022 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (Brudi PLUS)
Number of subjects: 109
Study 29475928 — intervention group
Group type: EXPERIMENTAL
Intervention: Thera tears (Group A)
Number of subjects: 45
Study 29475928 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet therapy (Group B)
Number of subjects: 45
Study 29475928 — intervention group
Group type: EXPERIMENTAL
Intervention: Tears Naturale free (Group C)
Number of subjects: 45
Study 29475928 — intervention group
Group type: COMPARATOR
Intervention: All groups (Thera tears, Wet therapy, Tears Naturale free)
Number of subjects: 45
Study 26350998 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 27
Study 26350998 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 27
Study 23235801 — intervention group
Group type: EXPERIMENTAL
Intervention: R-ACVBP (ACVBP plus rituximab)
Number of subjects: 223
Study 23235801 — intervention group
Group type: COMPARATOR
Intervention: ACVBP (control group)
Number of subjects: 223
Study 21787505 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl/TBO/light group (0.1%)
Number of subjects: 0
Study 21787505 — intervention group
Group type: COMPARATOR
Intervention: NaOCl (0.66%)
Number of subjects: 0
Study 21787505 — intervention group
Group type: COMPARATOR
Intervention: TBO/light groups (2.9%)
Number of subjects: 0
Study 19131173 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine OST (10mg QD, 8 days)
Number of subjects: 12
Study 19131173 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine ODT (10mg QD, 8 days)
Number of subjects: 12
Study 19131173 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 12
Study 16459721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG)
Number of subjects: 34
Study 16459721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 14672967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent normobaric hypoxia (Hyp)
Number of subjects: 14
Study 14672967 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (Norm)
Number of subjects: 14
Study 11782219 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopic eyes with low IOP readings
Number of subjects: 32918
Study 11782219 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing myopia
Number of subjects: 32918
Study 11782219 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal tension glaucoma
Number of subjects: 32918
Study 11782219 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing IOP
Number of subjects: 32918
Study 8935444 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486
Number of subjects: 12
Study 8935444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1563189 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic (14 days, n = 8)
Number of subjects: 13
Study 1563189 — intervention group
Group type: COMPARATOR
Intervention: Placebo (14 days, n = 4; 7 days, n = 1)
Number of subjects: 13
Study 1563189 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilators and physiotherapy
Number of subjects: 13
Study 4082879 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined general anaesthesia and epidural analgesia with etidocaine 1.5% intraoperatively and bupivacaine 0.5% 5 ml/4 h for 24 h and morphine 4 mg/12 h for 72 h
Number of subjects: 100
Study 4082879 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (low‐dose fentanyl) and systemic morphine for postoperative pain
Number of subjects: 100
Study 4082879 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia and low‐dose heparin
Number of subjects: 100
Study 4082879 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 100
Study 30932181 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 0
Study 30932181 — intervention group
Group type: COMPARATOR
Intervention: Interferon-β1a
Number of subjects: 0
Study 30172759 — intervention group
Group type: EXPERIMENTAL
Intervention: FTD/TPI
Number of subjects: 329
Study 30172759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study 26563287 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteosarcopenic
Number of subjects: 68
Study 26563287 — intervention group
Group type: COMPARATOR
Intervention: Sarcopenic
Number of subjects: 68
Study 26563287 — intervention group
Group type: COMPARATOR
Intervention: Osteopenic
Number of subjects: 68
Study 26563287 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 68
Study 25326007 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to the radio daily
Number of subjects: 855
Study 25326007 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving more services in ANC
Number of subjects: 855
Study 25326007 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving more delivery services
Number of subjects: 855
Study 25326007 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing disrespect and abuse during delivery
Number of subjects: 855
Study 22496085 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO) 500 mg intravenous bolus immediately before PPCI followed by a 12-hour infusion (50 mg/kg of body weight)
Number of subjects: 60
Study 22496085 — intervention group
Group type: COMPARATOR
Intervention: Normal saline bolus and infusion (placebo group)
Number of subjects: 60
Study 20173088 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnitrope lyophilisate
Number of subjects: 24
Study 20173088 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnitrope liquid
Number of subjects: 24
Study 20173088 — intervention group
Group type: COMPARATOR
Intervention: Genotropin
Number of subjects: 24
Study 17485956 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic parenteral antibiotics (carbapenems intravenously)
Number of subjects: 10
Study 17485956 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics)
Number of subjects: 10
Study 16284583 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Marcaine (treatment group, n = 15)
Number of subjects: 37
Study 16284583 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group, n = 22)
Number of subjects: 37
Study 16284583 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Marcaine and control)
Number of subjects: 37
Study 12235692 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigated group (carbohydrate metabolism disturbances)
Number of subjects: 80
Study 12235692 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal OGTT)
Number of subjects: 80
Study 9972757 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg of sufentanil plus 2.5 mg of bupivacaine (Group A)
Number of subjects: 42
Study 9972757 — intervention group
Group type: COMPARATOR
Intervention: Half the dose of sufentanil and bupivacaine (Group B)
Number of subjects: 42
Study 7751431 — intervention group
Group type: EXPERIMENTAL
Intervention: XR diltiazem 240 mg
Number of subjects: 189
Study 7751431 — intervention group
Group type: EXPERIMENTAL
Intervention: XR diltiazem 480 mg
Number of subjects: 189
Study 7751431 — intervention group
Group type: EXPERIMENTAL
Intervention: XR diltiazem (120-480 mg range)
Number of subjects: 189
Study 7751431 — intervention group
Group type: EXPERIMENTAL
Intervention: XR diltiazem
Number of subjects: 189
Study 7751431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 2112173 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental imagery technique for practicing ORCPR
Number of subjects: 0
Study 2112173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mental imagery)
Number of subjects: 0
Study 342300 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate 4 mg
Number of subjects: 93
Study 342300 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate 8 mg
Number of subjects: 93
Study 342300 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate 60 mg
Number of subjects: 93
Study 342300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 30543732 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPDGF-BB + β-TCP
Number of subjects: 12
Study 30543732 — intervention group
Group type: COMPARATOR
Intervention: β-TCP alone
Number of subjects: 12
Study 28494898 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 100
Study 28494898 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 100
Study 26116778 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute audio-instructed mindfulness meditation
Number of subjects: 60
Study 26116778 — intervention group
Group type: COMPARATOR
Intervention: 10-minute rest condition with audio-description of mindfulness meditation
Number of subjects: 60
Study 23369415 — intervention group
Group type: EXPERIMENTAL
Intervention: PBI plus booster brochures (PBI‐B)
Number of subjects: 443
Study 23369415 — intervention group
Group type: EXPERIMENTAL
Intervention: PBI
Number of subjects: 443
Study 23369415 — intervention group
Group type: COMPARATOR
Intervention: Assessment only control group (CNT)
Number of subjects: 443
Study 20921919 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (retested at 4 months)
Number of subjects: 24
Study 20921919 — intervention group
Group type: COMPARATOR
Intervention: Group B (retested at 8 months)
Number of subjects: 24
Study 20921919 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 24
Study 20921919 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 24
Study 19221759 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral renal embolization (URE)
Number of subjects: 16
Study 19221759 — intervention group
Group type: COMPARATOR
Intervention: Bilateral renal embolization (BRE)
Number of subjects: 16
Study 17056241 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline
Number of subjects: 36
Study 17056241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17056241 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol + Tiotropium
Number of subjects: 36
Study 14739799 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical attire
Number of subjects: 84
Study 14739799 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective gear
Number of subjects: 84
Study 14739799 — intervention group
Group type: COMPARATOR
Intervention: Both conditions
Number of subjects: 84
Study 9506205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IvIg)
Number of subjects: 0
Study 9506205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7923514 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 4%, 10%, 20%, 30%, 50% with 5-minute iontophoresis
Number of subjects: 20
Study 7923514 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 4%, 10%, 20%, 30%, 50% with 10-minute iontophoresis
Number of subjects: 20
Study 7923514 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 50% with 5-minute iontophoresis
Number of subjects: 20